These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 16377143

  • 1. FDA update.
    Katz R.
    Epilepsy Res; 2006 Jan; 68(1):85-94. PubMed ID: 16377143
    [Abstract] [Full Text] [Related]

  • 2. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL, Iyasu S.
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH, Johnson JR, Justice R, Pazdur R.
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL.
    Arch Intern Med; 2006 Oct 09; 166(18):1938-42. PubMed ID: 17030825
    [Abstract] [Full Text] [Related]

  • 10. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
    Hirschfeld S, Ho PT, Smith M, Pazdur R.
    J Clin Oncol; 2003 Mar 15; 21(6):1066-73. PubMed ID: 12637472
    [Abstract] [Full Text] [Related]

  • 11. Regulatory issues in pediatric psychopharmacology.
    Laughren TP.
    J Am Acad Child Adolesc Psychiatry; 1996 Oct 15; 35(10):1276-82. PubMed ID: 8885581
    [Abstract] [Full Text] [Related]

  • 12. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC, Farrell AT, Sridhara R, Pazdur R.
    Clin Cancer Res; 2006 May 15; 12(10):2955-60. PubMed ID: 16707588
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Criteria supporting the study of drugs in the newborn.
    Ward RM, Benitz WE, Benjamin DK, Blackmon L, Giacoia GP, Hudak M, Lasky T, Rodriguez W, Selen A.
    Clin Ther; 2006 Sep 15; 28(9):1385-98. PubMed ID: 17062311
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.
    Clin Cancer Res; 2006 Dec 15; 12(24):7271-8. PubMed ID: 17189398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.